While a number of IPOs have been pulled or delayed in 2026, the biotech sector has bucked the trend, with 26 companies debuting in U.S. markets.
Biotechs buck a sluggish IPO market, but investors should tread warily
While a number of IPOs have been pulled or delayed in 2026, the biotech sector has bucked the trend, with 26 companies debuting in U.S. markets.
Same Story from Other Publications
Compare how 6 other independent news outlets reported on this story.
Anthropic expected to receive high 'junk' rating from credit agencies following IPO, report says | TechCrunch
The new report says the AI lab will likely qualify for a high junk rating.
Securities Board of Nepal Divides IPO Pipeline Companies into 6 Stages
Kathmandu. The Securities Board of Nepal (SEBON) has divided companies in the primary share (IPO) issuance pipeline into 6 stages. The division is based on the status of 117 companies that have bee...
The open secret that could undermine Anthropic’s IPO
While investors digested projections hedged by warnings about threats to humanity, Anthropic also faces danger from the rising popularity of open-weights models.
Anthropic weighs up to 20% of IPO for retail as Warren demands answers
Retail money is ‘less sensitive to price’, a PitchBook analyst says, as Anthropic weighs up to 20% of its IPO for individuals and Warren presses on AI risk.
Anthropic files for potentially the biggest IPO ever as CEO warns of risk to humanity from AI
Artificial intelligence giant Anthropic filed paperwork Monday for what could be the biggest initial public offering of stock ever, even as its top executive warns that advanced AI could pose an existential threat to humanity.
Anthropic brings its mega IPO to Australia’s AI-starved investors
Australia is one of a few countries around the world where mum and dad investors can directly buy into the Anthropic IPO.